BR9915644A - Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus - Google Patents

Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus

Info

Publication number
BR9915644A
BR9915644A BR9915644-0A BR9915644A BR9915644A BR 9915644 A BR9915644 A BR 9915644A BR 9915644 A BR9915644 A BR 9915644A BR 9915644 A BR9915644 A BR 9915644A
Authority
BR
Brazil
Prior art keywords
compounds
virus
hepatitis
treatment
ketoesteroid
Prior art date
Application number
BR9915644-0A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Publication of BR9915644A publication Critical patent/BR9915644A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <B>"USO DE COMPOSTOS DE 17-CETOESTERóIDES E SEUS DERIVADOS, METABOLITOS E PRECURSORES NO TRATAMENTO DE VìRUS DE HEPATITE C E OUTROS TOGAVìRUS"<D>. A invenção provê o uso de compostos de 17-cetoesteróides, bem como derivados, metabolitos e precursores de tais compostos, e sais farmaceuticamente aceitáveis de qualquer um desses compostos, coletivamente definidos aqui os "compostos da presente invenção", no tratamento ou prevenção do vírus da hepatite do tipo C e/ou vírus da hepatite do tipo G em pacientes com necessidade de tal tratamento. Em adição, a invenção provê métodos para tratar ou prevenir infecções por togavírus, incluindo infecções por um ou mais alfavírus, flavivírus, tal como vírus da febre amarela, vírus da hepatite C, e vírus da hepatite G, vírus da rubéola ou pestivírus, tal como vírus da diarreía viral bovina. Em adição, a invenção provê terapias de combinação incluindo a administração de um ou mais compostos da presente invenção, conforme aqui definido, e administração de um ou mais compostos selecionados de compostos de aumento da concentração de plasma, fator de estimulação de macrófago, agentes de oxidação, ribavirin e interferon alfa, e/ou ventilação de oxigênio. Os compostos da presente invenção podem ser também usados para aliviar ou reduzir um ou mais sintomas associados à infecção por togavírus.
BR9915644-0A 1998-11-24 1999-11-24 Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus BR9915644A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992498P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028082 WO2000032177A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections

Publications (1)

Publication Number Publication Date
BR9915644A true BR9915644A (pt) 2001-08-07

Family

ID=27380740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915644-0A BR9915644A (pt) 1998-11-24 1999-11-24 Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus

Country Status (14)

Country Link
EP (1) EP1133287A2 (pt)
JP (1) JP2002531397A (pt)
KR (1) KR20010101074A (pt)
CN (1) CN1328463A (pt)
AP (1) AP2001002181A0 (pt)
AU (1) AU775614B2 (pt)
BR (1) BR9915644A (pt)
CA (1) CA2352205A1 (pt)
HK (1) HK1042426A1 (pt)
ID (1) ID29864A (pt)
IL (2) IL142942A0 (pt)
NZ (1) NZ511721A (pt)
OA (1) OA11716A (pt)
WO (1) WO2000032177A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
WO2001003681A2 (en) * 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
JP2005535664A (ja) 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
CA2496867A1 (en) * 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
PT2219642E (pt) * 2007-11-15 2011-10-18 Madaus Gmbh Componente de silibinina para o tratamento de hepatite
CN102993148B (zh) * 2011-09-13 2015-12-09 复旦大学 槲皮素衍生物或其类似物及其应用
WO2013178782A1 (en) * 2012-05-30 2013-12-05 Universidad De Zaragoza Allosteric inhibitors of ns3 protease from hepatitis c virus
CN108003212A (zh) * 2017-12-24 2018-05-08 扬州工业职业技术学院 一种去氢表雄酮-6-葡萄糖苷衍生物及其作为抗丙型肝炎病毒药物的应用
CN110452280B (zh) * 2019-07-25 2020-11-17 中国人民解放军第二军医大学 一类四环三萜酸衍生物及其制备方法与应用
CA3193390A1 (en) * 2020-09-22 2022-03-31 Andrey Factor Nebulizer and nebulized anti-virals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IL126623A0 (en) * 1996-04-17 1999-08-17 Prendergast Patrick T Pharmaceutical compositions and kits for dhea combined therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
WO2000032177A3 (en) 2001-03-22
AU3105200A (en) 2000-06-19
HK1042426A1 (zh) 2002-08-16
IL142942A0 (en) 2002-04-21
JP2002531397A (ja) 2002-09-24
EP1133287A2 (en) 2001-09-19
AP2001002181A0 (en) 2001-05-24
KR20010101074A (ko) 2001-11-14
IL142942A (en) 2006-08-20
CA2352205A1 (en) 2000-06-08
NZ511721A (en) 2004-07-30
CN1328463A (zh) 2001-12-26
ID29864A (id) 2001-10-18
WO2000032177A2 (en) 2000-06-08
OA11716A (en) 2005-01-25
AU775614B2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
NO20050466L (no) 2`- og 3`-nukleosid prodrug for behandling av flaviviridae infeksjoner
BR0312286A (pt) pró-medicamentos de 2&#39; e 3&#39; - nucleosìdeo modificado para tratamento de infecções por flaviviridae
NO20030337L (no) Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber
HUP0302334A2 (hu) Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására
BR9915644A (pt) Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
BR0205684A (pt) Compostos cìclicos fundidos e seu uso medicinal
DK0741577T3 (da) Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
NO20025600D0 (no) Fremgangsmåter og sammensetninger for behandling av flavivirus og pestivirus
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
BR0312278A (pt) éster 2&#39;-c-metil-3&#39;-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
ATE331515T1 (de) Verwendung von n-substituirten-1,5-dideoxy-1,5- imino-d-glucitolen zur behandlung von hepatitis infektionen
BRPI0415249A (pt) terapia de combinação para infecção por hcv
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
NO983090L (no) Terapeutiske forbindelser
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
BRPI0407140A (pt) Droga terapêutica para vìrus
NO931246L (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
ATE71840T1 (de) Virushemmende nukleosidmischung.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.